A prospective, randomized, controlled trial for the efficacy of baliximab induction in the blood-group incompatible peditric liver transplantation

A prospective, randomized, controlled for the efficacy of baliximab induction in the blood-group incompatible peditric liver transplantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019322

Enrollment

Unknown

Registered

2018-11-06

Start date

2018-11-20

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric liver transaplantation

Interventions

Group 1:Basiliximab induction

Group 2:without Basiliximab induction

Eligibility

Sex/Gender

All

Age

0.2 Years to 2 Years

Inclusion criteria

Inclusion criteria: Children conducted liver transplantation <24 months; be the first liver transplantation, in which the recipient received donor liver whose blood type did not conform to the blood transfusion principle

Exclusion criteria

Exclusion criteria: Multiple organ transplantation, retransplantation, previous immunomodulatory treatment

Design outcomes

Primary

Measure	Time frame
incidence of rejection;survival rate of graft;survival rate of recipient;the incidence of infection;new diseases;liver function;	—

Secondary

Measure	Time frame
peripheral blood of regulatory T cells (Treg) level;Growth and development;	—

Countries

China

Contacts

Public ContactWei Gao

Tianjin First Central Hospital

gao-wei@medmail.com.cn+86 13920128996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026